Evidence map›Paper›PMID 39527184›Full record

ArticleMolecular neurobiology2025

Copper Mitigates Atrazine-Induced Neurotoxicity in Parkinson's Disease Models.

Bingyun Li, Ruijiao Yang, Xiaojuan Chen, Jinyi He, Zijing Lu, Yanshu Li

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bingyun LiSchool of Public Health, Shantou University, Shantou, 515063, Guangdong Province, China.
Ruijiao Yang *Department of Toxicology, College of Public Health, Harbin Medical University, Harbin, 150081, Heilongjiang Province, China.
Xiaojuan Chen *School of Public Health, Shantou University, Shantou, 515063, Guangdong Province, China.
Jinyi HeSchool of Public Health, Shantou University, Shantou, 515063, Guangdong Province, China.
Zijing LuSchool of Public Health, Shantou University, Shantou, 515063, Guangdong Province, China.
Yanshu LiSchool of Public Health, Shantou University, Shantou, 515063, Guangdong Province, China. ysli@stu.edu.cn.

Funding

STU Scientific Research Initiation Grant NTF22027STU Scientific Research Initiation Grant NTF22028
6 · The paper itself

Abstract

Atrazine (ATR), one of the most prevalent herbicides used worldwide, has been associated with various environmental health concerns, including its potential role in promoting neurodegenerative diseases. Considering the pivotal role of metal homeostasis in the pathophysiology of neurodegenerative disorders, this study investigated the neuroprotective effects of copper supplementation in mitigating the adverse impacts of ATR in Parkinson's disease (PD). Our results reveal that ATR exposure disrupts copper and iron homeostasis within the substantia nigra pars compacta (SNpc), leading to enhanced oxidative stress and dopaminergic neuronal degeneration, which are key features of PD pathology. Remarkably, copper supplementation is able to counteract these neurotoxic effects, as demonstrated by the restoration of metal equilibrium in the SNpc, decreased lipid peroxidation, and improvements in motor function in PD rats. These results highlight the intricate relationship between environmental toxins and metal homeostasis in the genesis of neurodegenerative diseases.

Indexed as

AtrazineCopperParkinson DiseaseAnimalsDisease Models, AnimalDopaminergic NeuronsIronLipid PeroxidationMaleNeuroprotective AgentsOxidative StressPars CompactaRatsAtrazineCopperIronNeuroprotective AgentsAtrazineCeruloplasminFerroptosisParkinson's disease

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.